Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics Inc (DNTH) is a clinical-stage biotechnology company advancing DNTH103, a novel monoclonal antibody targeting complement pathways for autoimmune and neuromuscular disorders. This page provides investors and researchers with timely access to official press releases, clinical trial updates, and strategic developments.
Our curated collection includes updates on Phase 1/2 trials for conditions like generalized Myasthenia Gravis, regulatory milestones, and peer-reviewed data presentations. Users will find essential information about the company's selective C1s inhibition approach and subcutaneous administration technology without promotional bias.
Key content categories cover clinical progress reports, partnership announcements, and scientific conference insights. The resource is particularly valuable for tracking DNTH103's safety profile comparisons to existing therapies and its potential to reduce treatment frequency through YTE half-life extension.
Bookmark this page for streamlined access to verified DNTH developments. Check regularly for updates on trial enrollments, FDA communications, and new research validating the company's precision complement inhibition strategy.
Dianthus Therapeutics, a clinical-stage biotech company focused on developing antibody complement therapeutics for autoimmune diseases, has announced its participation in two major investor events.
The company will be featured at:
- Baird Biotech Discovery Series - CEO Marino Garcia will join a fireside chat on May 6, 2025, at 1:30 p.m. EDT
- Bank of America 2025 Health Care Conference - Garcia will present a corporate overview on May 14, 2025, at 5:35 p.m. EDT and conduct one-on-one investor meetings
Both presentations will be accessible via webcast through the "News and Events" section of Dianthus Therapeutics' investor website.
Dianthus Therapeutics (DNTH) has reported its Q4 and FY 2024 financial results, highlighting significant progress in its clinical trials. The company's lead candidate DNTH103, a monoclonal antibody targeting the classical complement pathway, is advancing in multiple trials:
- Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) with top-line results expected in 2H'25
- Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with interim analysis in 2H'26
- Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) with results expected in 2H'26
Financial highlights include:
- Cash position of $357.0 million providing runway into 2H'27
- R&D expenses increased to $83.1 million in 2024
- Net loss of $85.0 million or $2.55 per share
- G&A expenses reached $25.0 million
Dianthus Therapeutics (NASDAQ: DNTH) has announced two key leadership appointments to strengthen its commercial capabilities. John C. King joins as Chief Commercial Officer, bringing over 25 years of global commercial leadership experience, particularly in complement inhibitor therapies for neuromuscular and hematological rare diseases.
King's notable achievements include launching the first approved biologic and C5 complement inhibitor in the Myasthenia Gravis market at Alexion, and leading commercial strategy for Ra Pharma's first FDA-approved self-administered subcutaneous biologic for gMG, which led to Ra Pharma's $2.5 billion acquisition by UCB.
Additionally, Sujay Kango, with 26+ years of industry experience, joins the Board of Directors. Kango's experience includes serving as CEO of Tmunity Therapeutics (acquired by Gilead) and EVP/CCO of Acceleron Pharma (acquired by Merck for $11.5B). The company also announced that Tomas Kiselak will transition from the Board of Directors.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in two upcoming investor conferences.
The company will participate in the TD Cowen 45th Annual Health Care Conference, where CEO Marino Garcia will conduct a fireside chat on March 5, 2025, at 11:50 a.m. ET in Boston. The presentation will be available via webcast on the company's website under the Investors section.
Additionally, Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025, in Miami.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing antibody complement therapeutics for severe autoimmune diseases, has announced its upcoming participation in two major investor conferences in February 2025.
The company's CEO, Marino Garcia, will present at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET, which will be held virtually.
Interested parties can access live webcasts of both presentations through the 'News and Events' section of the Investors page on Dianthus Therapeutics' website.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The company's CEO, Marino Garcia, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. Interested parties can access a live webcast of the presentation through the 'News and Events' section of the Investors page on the Dianthus Therapeutics website.
Dianthus Therapeutics (NASDAQ: DNTH) reported Q3 2024 financial results and business updates. The company plans to initiate a pivotal Phase 3 trial of DNTH103 in CIDP by year-end 2024, while Phase 2 trials in gMG and MMN are ongoing with results expected in 2H'25 and 2H'26, respectively. Financial highlights include $342.6 million cash position providing runway into 2H'27, Q3 R&D expenses of $25.5 million, and a net loss of $25.2 million ($0.74 per share). DNTH103, their lead candidate, is designed for subcutaneous administration every two weeks in treating autoimmune disorders.
Dianthus Therapeutics (Nasdaq: DNTH) has announced its participation in three major healthcare investor conferences. CEO Marino Garcia will present corporate overviews at the Guggenheim Healthcare Innovation Conference (November 11, 1:30 p.m. ET, Boston), Jefferies Global Healthcare Conference (November 19, 9:00 a.m. GMT, London), and 7th Annual Evercore HealthCONx Conference (December 4, 10:50 a.m. ET, Coral Gables). Live webcasts will be available on the company's website under the Investors section.
Dianthus Therapeutics (Nasdaq: DNTH) announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor specific to the active form of C1s, being evaluated for generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy.
The presentations will showcase:
- Preclinical and in vitro data on DNTH103's potentially differentiated profile in disease models of gMG and CIDP
- Head-to-head affinity and pharmacodynamic potency data comparing DNTH103 to riliprubart
- DNTH103's sustainable inhibition of complement and prevention of nerve conduction velocity impairment in a CIDP preclinical model
- DNTH103 as a potentially safer and more convenient novel therapy for generalized Myasthenia Gravis
The posters will be available on the Dianthus website after presentation.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2024. CEO Marino Garcia will present corporate overviews at:
1. Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
2. Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom
Live webcasts of the Cantor and Stifel conference presentations will be available on the company's website under the Investors section.
FAQ
What is the current stock price of Dianthus Therapeutics (DNTH)?
What is the market cap of Dianthus Therapeutics (DNTH)?
